EWM
VKTX icon

Edge Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Edge Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed -$1K – 686
2019
Q4 		$1K Hold
100
– – ﹤0.01% 570
2019
Q3 		$0 Hold
100
– – ﹤0.01% 641
2019
Q2 		$1K Sell
100
-5
-5% -$43 ﹤0.01% 577
2019
Q1 		$1K Buy
105
+100
+2,000% +$837 ﹤0.01% 543
2018
Q4 		$0 Hold
5
– – ﹤0.01% 626
2018
Q3 		$1K Buy
+5
New +$60 ﹤0.01% 588

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Edge Wealth Management's VKTX Position: Q1 2020 in Review

Edge Wealth Management sold out of Viking Therapeutics (VKTX) in Q1 2020, closing a stake of 100 shares — an estimated $1K sold.

Edge Wealth Management first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $1K in Q4 2019. 137 funds tracked by Wall St. Rank hold VKTX as of Q1 2020.

  • Edge Wealth Management reported no remaining Viking Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Edge Wealth Management sold 100 Viking Therapeutics shares in Q1 2020, an estimated $1K.
  • Edge Wealth Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
  • Edge Wealth Management's Viking Therapeutics position peaked at $1K in Q4 2019.
  • 137 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2020.

Based on Edge Wealth Management's 13F filing for Q1 2020, filed 20 Apr 2020.